comparemela.com

Latest Breaking News On - Flumatinib xinfu - Page 1 : comparemela.com

TiumBio and Hansoh Pharma Announce Clinical Trial Approval of HS-10518/TU2670 from NMPA in China

/PRNewswire/ TiumBio Co., Ltd. (KOSDAQ: 321550), a clinical-stage biopharmaceutical company focusing on discovering and development innovative therapeutics.

United statesKyonggi doSouth koreaSun yuanFlumatinib xinfuSuna choMorinidazole mailingdaHansoh pharmaInebilizumab xinyueAumolertinib ameileHansoh pharmaceutical group co ltdPrnewswire tiumbio co ltdHansoh pharmaceutical groupChina national medical products administrationTiumbio co ltdCorporate communications investor relations

Biotheus has entered into a license and collaboration agreement with Hansoh Pharma for its EGFR/MET bispecific antibody in the Greater China territory

ZHUHAI, China, Nov. 14, 2022 /PRNewswire/ Biotheus Inc., a clinical-stage biotech company focused on the discovery and development of biologics.

United statesHong kongMacau generalAlmonertinib ameileFlumatinib xinfuTenofovir amibufenamideInebilizumab xinyueXiaolin liuMorinidazole mailingdaYun sunHansoh pharmaHansoh pharmaceuticalsPrnewswire biotheus incBiotheus incGreater chinaMainland china

KiOmed Pharma and Hansoh Pharma Announce License Agreement for KiOmedinevsOne in China s Mainland, Macau and Taiwan - Press Release

- KiOmedinevsOne is a non-animal sourced chitosan injection that has been launched in Europe for the treatment of knee osteoarthritis. - KiOmed Pharma

Almonertinib ameileFlumatinib xinfuTenofovir amibufenamideInebilizumab xinyueEliza sunKiomed pharmaAgaricus bisporusMorinidazole mailingdaHansoh pharmaHansoh pharmaceutical groupHansoh pharmaceutical group company limitedOmed pharmaExecutive chairmanManaging directorExecutive director

Hansoh Pharmaceutical Group Company Limited: KiOmed Pharma and Hansoh Pharma Announce License Agreement for KiOmedinevsOne in China s Mainland, Macau and Taiwan

KiOmedinevsOne is a non-animal sourced chitosan injection that has been launched in Europe for the treatment of knee osteoarthritis. KiOmed Pharma is eligible to receive upfront fee and milestone

Almonertinib ameileFlumatinib xinfuTenofovir amibufenamideInebilizumab xinyueEliza sunKiomed pharmaAgaricus bisporusMorinidazole mailingdaHansoh pharmaSophia dongHansoh pharmaceutical groupHansoh pharmaceutical group company limitedGlobal business developmentOmed pharmaExecutive chairmanManaging director

vimarsana © 2020. All Rights Reserved.